A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.

Authors: Fionnuala Crowley, Natalie Lucas, Kathy Wu, Jessica Wilk, Olivia Hapanowicz, Lisa Fitzgerald, Matthew Park, Nicholas Cole Rohs, Nicholas James Venturini, David F. Yankelevitz, Udit Chaddha, Timothy Harkin, Mary Beth Beasley, Daniel Nicastri, Ardeshir Hakami-kermani, Brian Housman, Deborah Blythe Doroshow, Andrew Kaufman, Miriam Merad, Thomas Urban Marron

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2696

Source: Full article

---

Abstract

TPS2696